Clinically-meaningful improvements in therapy for unresectable NSCLC
Author:
Affiliation:
1. Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Funder
no funding to report
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14737140.2022.2102483
Reference91 articles.
1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
2. Validation of the Eighth Edition TNM Lung Cancer Staging System
3. Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010
4. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
5. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. SETD1A‐mediated H3K4me3 methylation upregulates lncRNA HOXC‐AS3 and the binding of HOXC‐AS3 to EP300 and increases EP300 stability to suppress the ferroptosis of NSCLC cells;Thoracic Cancer;2023-08-07
2. SMARCA4: Current status and future perspectives in non-small-cell lung cancer;Cancer Letters;2023-02
3. Pharmacokinetics, tissue distribution, and antitumor activity of a novel compound, NY-2, in non-small cell lung cancer;Frontiers in Pharmacology;2023-01-16
4. Palliative Radiotherapy for Non-metastatic Non-small-cell Lung Cancer: Impact of Blood Test Results on Survival;In Vivo;2023
5. Foxm1 Promotes the Progression of Non-Small Cell Lung Cancer by Inhibiting Mir-509-5p Expression Via Binding to the Mir-509-5p Promoter Region;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3